- Home
- MIRM vs PAM Comparison
MIRM vs PAM Comparison
Compare MIRM & PAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- PAM
- Stock Information
- Founded
- MIRM 2018
- PAM 1945
- Country
- MIRM United States
- PAM Argentina
- Employees
- MIRM N/A
- PAM 1847
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- PAM Electric Utilities: Central
- Sector
- MIRM Health Care
- PAM Utilities
- Exchange
- MIRM Nasdaq
- PAM Nasdaq
- Market Cap
- MIRM 3.8B
- PAM 4.5B
- IPO Year
- MIRM 2019
- PAM N/A
- Fundamental
- Price
- MIRM $69.89
- PAM $81.52
- Analyst Decision
- MIRM Strong Buy
- PAM Hold
- Analyst Count
- MIRM 11
- PAM 2
- Target Price
- MIRM $79.00
- PAM $92.75
- AVG Volume (30 Days)
- MIRM 580.7K
- PAM 451.7K
- Earning Date
- MIRM 11-04-2025
- PAM 11-04-2025
- Dividend Yield
- MIRM N/A
- PAM N/A
- EPS Growth
- MIRM N/A
- PAM N/A
- EPS
- MIRM N/A
- PAM 0.33
- Revenue
- MIRM $429,161,000.00
- PAM $1,875,000,000.00
- Revenue This Year
- MIRM $53.14
- PAM $142,276.70
- Revenue Next Year
- MIRM $19.83
- PAM $29.06
- P/E Ratio
- MIRM N/A
- PAM $10.37
- Revenue Growth
- MIRM 62.33
- PAM N/A
- 52 Week Low
- MIRM $36.88
- PAM $54.95
- 52 Week High
- MIRM $78.55
- PAM $97.55
- Technical
- Relative Strength Index (RSI)
- MIRM 43.37
- PAM 71.24
- Support Level
- MIRM $68.34
- PAM $74.02
- Resistance Level
- MIRM $71.86
- PAM $84.07
- Average True Range (ATR)
- MIRM 2.36
- PAM 4.29
- MACD
- MIRM -0.43
- PAM 2.36
- Stochastic Oscillator
- MIRM 28.92
- PAM 79.25
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.